SwissDiab Study: Lipid Biomarker Targets in 216 Patients with Type 1 Diabetes

A clinical study dataset of 216 adult patients with type 1 diabetes mellitus enrolled in the SwissDiab study. The data evaluates target attainment for three lipid biomarkers—LDL-C, non-HDL-C, and apolipoprotein B—according to 2021 European Society of Cardiology guidelines. The dataset was authored by Christina Liu and last updated on 2026-05-29.

Use Cases

• Assessing discordance in cardiovascular risk classification based on LDL-C, non-HDL-C, and apolipoprotein B targets mentioned in the description.
• Analyzing the prevalence of lipid-lowering therapy prescription in a type 1 diabetes cohort.
• Evaluating the association between patient demographics (age, diabetes duration, HbA1c) and lipid target attainment.
• Benchmarking clinical guideline adherence for lipid management in a specific patient population.

Strengths

• Includes data for 216 patients with specific median values: age 43.6 years, diabetes duration 16 years, and HbA1c 7.3%.
• Reports target attainment percentages for three distinct lipid biomarkers: LDL-C (11.6%), non-HDL-C (30.6%), and apolipoprotein B (59.7%).
• Provides detailed cardiovascular risk stratification, with 75.0% of patients at high and 11.6% at very high risk.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (70.5 KB), indicating limited scope and sample size.

Provenance

Source

figshare, authored by Christina Liu.

Collection Method

Data appears to be from the SwissDiab study, a clinical research cohort.

Freshness

Last updated 2026-05-29 04:49:03; freshness should be verified.

Geography

Likely Switzerland, inferred from the study name 'SwissDiab'.